Abstract Body

Background: CMV-infection is highly prevalent among HIV-infected patients. We investigated its impact on immune reconstitution in HIV-infected patients receiving their first cART.

Methods: From the French multicenter Dat’AIDS cohort, we selected patients who initiated a first cART between 2002 and 2009, maintained an undetectable plasma viral load (pVL) for at least 12 months with the same cART regimen and had a known CMV serostatus. T-cell immunophenotyping was performed before cART initiation (pre-cART), at the first undetectable pVL (D0), and every 6 months during 3 yrs.

Results: 5,688 patients initiated a first cART during the study period, 503 of whom fulfilled the selection criteria (74% male, median age 43 yrs, 15.5% CDC stage C), distributed in 444(88.3%) CMV+ and 69 CMV -. Median CD4 nadir (222/mm3) and exposure to first-line cART (32.3 months) were not different by CMV status. Chronic hepatitis C (HCV-PCR+) was equally prevalent (5.2%) in CMV+ and CMV- patients. Median follow-up was shorter in CMV+(1[0.2;3.4] yrs) than in CMV- (3.4[0.3;8.4]yrs, p<0.05). Both groups had similar median pre-cART CD4 (250[162;319]/mm3) and pre-cART CD8 (772[530;1123]/mm3) values. After 3 yrs, CD4 reconstitution was comparable between the groups, while absolute and differential CD8 cell counts were higher in CMV+ (816[583;1017] vs. 615[383;849]/mm3 in CMV-, p<0.001). Bivariate analysis revealed a negative correlation between CMV+ serology and CD4/CD8 ratio from D0 of HIV suppression (Figure 1: box plot & Pearson’s R). Linear regression analyses using CD8 or CD4/CD8 ratio as dependent variables, and CMV serology, duration of HIV exposure, CD4 nadir and cART regimen as independent variables, confirmed a negative correlation between CMV+ serology and CD4/CD8 ratio after 1, 2 and 3 yrs of cART initiation (p<0.05, <0.001 and <0.001, respectively).

Conclusions: CMV+ serostatus is associated with poorer immunological response to cART initiation compared to CMV- serostatus despite efficient control of HIV replication. Thus, CMV serological status should be taken into account when measuring the effectiveness of antiretroviral therapy on immune restoration.

viewer?TAG_ACTION=SECURE_FILE_DOWNLOAD&V